Description
Using our intelligently designed and intuitive dataset, you can quickly understand how Omnicell, Inc. (OMCL) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.
Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.
For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.
Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.
Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:
1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.
2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.
3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).
4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.
5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).
6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).
7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).
Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].
Frequently Asked Questions
What is Omnicell, Inc. (OMCL) lobbying for?
Summary of lobbying data for Omnicell, Inc.:
– Lobbying firms hired: Wexford Solutions Llc, Polsinelli Pc
– General issues lobbied on: Medicare/Medicaid, Health Issues
– Specific issues lobbied on:
– Issues related to patient safety and quality
– Issues related to the implementation of the Drug Quality & Security Act (Public Law 113-54)
– HR 7518 The Safer Compounding in Hospitals Act
– Discuss importance of 340B drug discount program and policy matters related to the program.
– Issues pertaining to the Medicare programs treatment of automated drug compounding technology
– Government agencies lobbied: Senate, Food & Drug Administration (FDA), Centers For Medicare and Medicaid Services (CMS), House of Representatives
One could infer that Omnicell, Inc. is lobbying on these specific issues related to patient safety and quality, drug quality and security, and Medicare/Medicaid policies because they are a healthcare technology company that provides medication and supply dispensing systems for healthcare facilities. The Safer Compounding in Hospitals Act (HR 7518) and issues related to the implementation of the Drug Quality & Security Act (Public Law 113-54) are both relevant to their business, as they aim to improve the safety and quality of medications administered to patients. Additionally, the discussions of the Medicare programs treatment of automated drug compounding technology and the importance of the 340B program are likely related to potential policies that could either positively or negatively impact Omnicell’s business.
